We advised the joint book-running managers and underwriters on the offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by REGENXBIO Inc. of 11,671,139 shares of common stock at $9.00 per share and pre-funded warrants to purchase 1,111,111 shares of common stock at $8.9999 per pre-funded warrant, for total gross proceeds of approximately $115 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RGNX.”

Based in Rockville, Maryland, REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The company’s investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO has developed a broad pipeline of gene therapy programs using NAV Technology Platform as a one-time treatment to address an array of diseases.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Hope Goimarac and Josh Mimura. Partner David R. Bauer and associate Ryan Grawe provided intellectual property advice. The tax team included counsel Dustin Plotnick and associates Hunter P. Shaw and Alanna Phillips. All members of the Davis Polk team are based in the New York office.

Copy link to share post